期刊
INFECTION AND DRUG RESISTANCE
卷 12, 期 -, 页码 1597-1615出版社
DOVE MEDICAL PRESS LTD
DOI: 10.2147/IDR.S207572
关键词
antibiotics; fecal matter transfer; polyclonal adjuvants; C. difficile; biotherapeutic agents
资金
- National Research Foundation of Korea (NRF) - Korean government (MEST) [2017R1A2B4012636]
- Gachon University [GCU-2018-0682]
Clostridium difficile (C. difficile) is rapidly becoming one of the most prevalent health care-associated bacterial infections in the developed world. The emergence of new, more virulent strains has led to greater morbidity and resistance to standard therapies. The bacterium is readily transmitted between people where it can asymptomatically colonize the gut environment, and clinical manifestations ranging from frequent watery diarrhea to toxic megacolon can arise depending on the age of the individual or their state of gut dysbiosis. Several inexpensive approaches are shown to be effective against virulent C. difficile in research settings such as probiotics, fecal microbiota transfer and immunotherapies. This review aims to highlight the current advantages and limitations of the aforementioned approaches with an emphasis on recent studies.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据